OBJECTIVES: The STRIDE study assessed whether a lifestyle intervention, tailored for individuals with serious mental illnesses, reduced weight and diabetes risk. The authors hypothesized that the STRIDE intervention would be more effective than usual care in reducing weight and improving glucose metabolism. METHOD: The study design was a multisite, parallel two-arm randomized controlled trial in community settings and an integrated health plan. Participants who met inclusion criteria were ≥18 years old, were taking antipsychotic agents for ≥30 days, and had a body mass index ≥27. Exclusions were significant cognitive impairment, pregnancy/breastfeeding, recent psychiatric hospitalization, bariatric surgery, cancer, heart attack, or stroke. The intervention emphasized moderate caloric reduction, the DASH (Dietary Approaches to Stop Hypertension) diet, and physical activity. Blinded staff collected data at baseline, 6 months, and 12 months. RESULTS:Participants (men, N=56; women, N=144; mean age=47.2 years [SD=10.6]) were randomly assigned to usual care (N=96) or a 6-month weekly group intervention plus six monthly maintenance sessions (N=104). A total of 181 participants (90.5%) completed 6-month assessments, and 170 (85%) completed 12-month assessments, without differential attrition. Participants attended 14.5 of 24 sessions over 6 months. Intent-to-treat analyses revealed that intervention participants lost 4.4 kg more than control participants from baseline to 6 months (95% CI=-6.96 kg to -1.78 kg) and 2.6 kg more than control participants from baseline to 12 months (95% CI=-5.14 kg to -0.07 kg). At 12 months, fasting glucose levels in the control group had increased from 106.0 mg/dL to 109.5 mg/dL and decreased in the intervention group from 106.3 mg/dL to 100.4 mg/dL. No serious adverse events were study-related; medical hospitalizations were reduced in the intervention group (6.7%) compared with the control group (18.8%). CONCLUSIONS:Individuals taking antipsychotic medications can lose weight and improve fasting glucose levels. Increasing reach of the intervention is an important future step.
RCT Entities:
OBJECTIVES: The STRIDE study assessed whether a lifestyle intervention, tailored for individuals with serious mental illnesses, reduced weight and diabetes risk. The authors hypothesized that the STRIDE intervention would be more effective than usual care in reducing weight and improving glucose metabolism. METHOD: The study design was a multisite, parallel two-arm randomized controlled trial in community settings and an integrated health plan. Participants who met inclusion criteria were ≥18 years old, were taking antipsychotic agents for ≥30 days, and had a body mass index ≥27. Exclusions were significant cognitive impairment, pregnancy/breastfeeding, recent psychiatric hospitalization, bariatric surgery, cancer, heart attack, or stroke. The intervention emphasized moderate caloric reduction, the DASH (Dietary Approaches to Stop Hypertension) diet, and physical activity. Blinded staff collected data at baseline, 6 months, and 12 months. RESULTS:Participants (men, N=56; women, N=144; mean age=47.2 years [SD=10.6]) were randomly assigned to usual care (N=96) or a 6-month weekly group intervention plus six monthly maintenance sessions (N=104). A total of 181 participants (90.5%) completed 6-month assessments, and 170 (85%) completed 12-month assessments, without differential attrition. Participants attended 14.5 of 24 sessions over 6 months. Intent-to-treat analyses revealed that intervention participants lost 4.4 kg more than control participants from baseline to 6 months (95% CI=-6.96 kg to -1.78 kg) and 2.6 kg more than control participants from baseline to 12 months (95% CI=-5.14 kg to -0.07 kg). At 12 months, fasting glucose levels in the control group had increased from 106.0 mg/dL to 109.5 mg/dL and decreased in the intervention group from 106.3 mg/dL to 100.4 mg/dL. No serious adverse events were study-related; medical hospitalizations were reduced in the intervention group (6.7%) compared with the control group (18.8%). CONCLUSIONS: Individuals taking antipsychotic medications can lose weight and improve fasting glucose levels. Increasing reach of the intervention is an important future step.
Authors: Lawrence J Appel; Catherine M Champagne; David W Harsha; Lawton S Cooper; Eva Obarzanek; Patricia J Elmer; Victor J Stevens; William M Vollmer; Pao-Hwa Lin; Laura P Svetkey; Sarah W Stedman; Deborah R Young Journal: JAMA Date: 2003 Apr 23-30 Impact factor: 56.272
Authors: Bobbi Jo H Yarborough; Shannon L Janoff; Victor J Stevens; David Kohler; Carla A Green Journal: Transl Behav Med Date: 2011-09-01 Impact factor: 3.046
Authors: Sarah Stark Casagrande; Cheryl A M Anderson; Arlene Dalcin; Lawrence J Appel; Gerald J Jerome; Faith B Dickerson; Joseph V Gennusa; Gail L Daumit Journal: Psychiatr Rehabil J Date: 2011
Authors: Jaana Lindström; Pirjo Ilanne-Parikka; Markku Peltonen; Sirkka Aunola; Johan G Eriksson; Katri Hemiö; Helena Hämäläinen; Pirjo Härkönen; Sirkka Keinänen-Kiukaanniemi; Mauri Laakso; Anne Louheranta; Marjo Mannelin; Merja Paturi; Jouko Sundvall; Timo T Valle; Matti Uusitupa; Jaakko Tuomilehto Journal: Lancet Date: 2006-11-11 Impact factor: 79.321
Authors: Amy M Kilbourne; Jack R Cornelius; Xiaoyan Han; Harold A Pincus; Mujeeb Shad; Ihsan Salloum; Joseph Conigliaro; Gretchen L Haas Journal: Bipolar Disord Date: 2004-10 Impact factor: 6.744
Authors: Jamy D Ard; Steve C Grambow; Di Liu; Cris A Slentz; William E Kraus; Laura P Svetkey Journal: Diabetes Care Date: 2004-02 Impact factor: 19.112
Authors: Marion J Franz; Jeffrey J VanWormer; A Lauren Crain; Jackie L Boucher; Trina Histon; William Caplan; Jill D Bowman; Nicolas P Pronk Journal: J Am Diet Assoc Date: 2007-10
Authors: Christina Mangurian; Aishat Giwa; Erin Brosey; Martha Shumway; James Dilley; Elena Fuentes-Afflick; Eliseo J Pérez-Stable; Dean Schillinger Journal: J Am Board Fam Med Date: 2019 May-Jun Impact factor: 2.657
Authors: John A Naslund; Karen L Whiteman; Gregory J McHugo; Kelly A Aschbrenner; Lisa A Marsch; Stephen J Bartels Journal: Gen Hosp Psychiatry Date: 2017-04-06 Impact factor: 3.238
Authors: Stephen J Bartels; Sarah I Pratt; Kelly A Aschbrenner; Laura K Barre; John A Naslund; Rosemarie Wolfe; Haiyi Xie; Gregory J McHugo; Daniel E Jimenez; Ken Jue; James Feldman; Bruce L Bird Journal: Am J Psychiatry Date: 2014-12-12 Impact factor: 18.112
Authors: John A Naslund; Kelly A Aschbrenner; Emily A Scherer; Sarah I Pratt; Rosemarie S Wolfe; Stephen J Bartels Journal: Am J Prev Med Date: 2015-09-16 Impact factor: 5.043